NXL — Nexalin Technology, Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1527352 ·
Last close
$0.43
Market Cap
$9.28M
52W High
$0.64
52W Low
$0.31
ADV30
993,643
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 14,950 | 13,133 | -2,119,902 | -2,096,837 | 3,694,633 | 1,207,895 | 808,364 |
| Dec 2025 | 171,895 | 150,866 | -2,413,167 | -2,376,546 | 4,635,319 | 654,783 | 887,333 |
| Sep 2025 | 18,149 | 14,201 | -2,345,631 | -2,276,311 | 5,125,940 | 590,075 | 357,524 |
| Jun 2025 | 70,588 | 47,750 | -1,620,858 | -1,580,987 | 6,563,982 | 431,320 | 600,584 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,957,658
Investing CF
$-131,991
Financing CF
$5,039,734
CapEx
$-96,859
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.61
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-92,867,412
Inventory
$131,473
Receivables
$81,571
ST Investments
$3,068,429
EBIT TTM
$-8,390,881
Pretax Income TTM
$-8,221,133
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$275,582
EBITDA
$-8,471,964
Free Cash Flow
$-2,250,682
Enterprise Value
$6,162,204
Total Cash
$2,708,485
Total Debt
$0
Shares Out
21,540,662
Trailing EPS
$-0.46
Book Value
$0.14
ROE
-319.7%
ROA
-161.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 301,647 | -8,390,881 | -8,222,181 | 4,635,319 | 887,333 | — | -4,957,658 |
| Dec 2024 | 168,721 | -7,754,646 | -7,607,182 | 4,222,732 | 546,694 | — | -3,944,390 |
| Dec 2023 | 110,748 | -5,696,296 | -4,648,709 | 3,631,916 | 425,281 | — | -3,835,384 |
| Dec 2022 | 1,321,357 | -1,833,031 | -1,697,816 | 7,432,136 | 1,953,449 | — | -2,215,699 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.31
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALUR | ALLURION TECHNOLOGIES, INC. | $9.90M | $0.66 | — |
| DROR | Dror Ortho-Design, Inc. | $8.50M | $0.01 | — |
| MBAI | Check-Cap Ltd | $10.75M | $1.39 | — |
| VVOS | Vivos Therapeutics, Inc. | $7.95M | $0.57 | — |
| RGNT | REGENTIS BIOMATERIALS LTD. | $7.77M | $1.50 | — |
News headlines (Yahoo Finance, 1h cache)
Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Qu
2026-06-10 13:15 · Yahoo
EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life
2026-06-10 13:01 · Yahoo
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
2026-06-04 14:00 · Yahoo
Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Vete
2026-05-21 12:30 · Yahoo
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
2026-05-19 12:30 · Yahoo
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
2026-04-28 13:15 · Yahoo
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
2026-04-22 13:35 · Yahoo
RedChip's Biotech Investor Conference Replays Now Available
2026-04-20 12:00 · Yahoo
April 2026 Global's Top Undervalued Small Caps With Insider Action
2026-04-17 09:39 · Yahoo
ASX Stocks That May Be Trading Below Their Estimated Value
2026-04-16 19:34 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.